June 14, 2019 EHA 2019 – turnaround puts Arqule in the takeover frame A key update confirms ARQ 531 as the leading contender to treat patients who relapse on Imbruvica or Calquence.
March 14, 2019 Imbruvica resistance provides early but fertile development ground Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
